In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species
about
Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenesEfficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm.In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United StatesPrevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.Ribosomal mutations in Streptococcus pneumoniae clinical isolatesKetolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Telithromycin: an oral ketolide for respiratory infections.Ketolides in the treatment of respiratory infections.Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.Streptococcus pneumoniae isolates resistant to telithromycin.Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000.High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniaeApplication of molecular genetic methods in macrolide, lincosamide and streptogramin resistance diagnostics and in detection of drug-resistant Mycobacterium tuberculosis.Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.Cethromycin: a promising new ketolide antibiotic for respiratory infections.Speculative strategies for new antibacterials: all roads should not lead to Rome.Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA.Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.Methylation of 23S rRNA nucleotide G748 by RlmAII methyltransferase renders Streptococcus pneumoniae telithromycin susceptible.Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.In vitro activity of telithromycin against mefA and ermB erythromycin-resistant viridans streptococci isolated from bacteremia of oral origin in Spain.Presence and mechanism of macrolide-lincosamide resistance in Enterococcus columbae strains belonging to the intestinal flora of pigeons.Alterations in regulatory regions of erm(B) genes from clinical isolates of enterococci resistant to telithromycin
P2860
Q24791672-A0FB1BAB-C052-49F4-AAAB-555A151B1684Q24813259-2468FA9E-AC91-4F16-9B6E-8F4BCC332778Q30806051-85BF273A-6411-420F-9391-6F9B4092FFBAQ33187513-92141D11-1A20-4DAD-A379-9ED6F85C0F30Q33224241-D4255402-DE81-4A39-AAE2-F857D92B3514Q33836624-9FBC0136-7D65-4E71-BEFE-1D340B4EEBB6Q34076998-1D29C8A2-6951-4487-941C-3A38C131714CQ34113722-AAD45BD3-9AE4-4647-AB27-0EF53C69818DQ34281970-3B505190-4BE3-4CDC-8C6F-82B17FC6C101Q34401542-2F32AD02-A75E-4063-8AC3-64C520EA25FBQ34544732-9F3F8901-79D4-4D38-B98E-C17CB4593DDAQ34547639-8B641D95-C40B-4E50-A0EC-B02C7ACB5FA2Q34648611-A6812816-891B-4EEE-B527-E2291738D6BBQ34735517-CDFE8A22-9BE3-40E7-A5FF-68774ED48110Q34820774-CD820BC8-F916-48A5-BD6B-E02C3291DE33Q35014269-36400807-F221-4AF4-BA87-A74707100BD3Q35647682-974D4BD6-82DF-481C-B5DA-608082BE1195Q36003067-A85A11CE-2FC6-4710-B15B-70D49E263D0CQ36425045-0120A790-57E1-4F2B-B314-021EB427D956Q37697782-8429CC2D-22E3-4F5E-92E6-79C3075043A9Q38101243-FE029C3E-49CE-4D4C-997B-467721832E3DQ39651945-571EBA7C-FB1F-41AF-A344-376FC62B08A6Q40165104-DCD461F3-8C51-4E89-B797-F671722E0B8DQ41791211-C3813ACF-D0C5-49BC-A02C-DF0B120361B6Q44770176-00C7D9BC-1189-4F32-B949-B0F6297164D7Q45197075-2CF3D86E-482F-438E-AA75-1ED69BFD1178Q47273510-FAE9486B-78A8-461E-9849-8B230D632478Q57226019-70030313-CBBC-416F-9E43-DE154E4DB78B
P2860
In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro activities of the nov ...... esistant Streptococcus species
@ast
In vitro activities of the nov ...... esistant Streptococcus species
@en
type
label
In vitro activities of the nov ...... esistant Streptococcus species
@ast
In vitro activities of the nov ...... esistant Streptococcus species
@en
prefLabel
In vitro activities of the nov ...... esistant Streptococcus species
@ast
In vitro activities of the nov ...... esistant Streptococcus species
@en
P2093
P2860
P1476
In vitro activities of the nov ...... esistant Streptococcus species
@en
P2093
P2860
P304
P356
10.1128/AAC.45.3.789-793.2001
P407
P577
2001-03-01T00:00:00Z